AQST: Aquestive Pharma Company Value to Net Income

Corporate emblem and logo of Aquestive Therapeutics Inc (AQST)

Complex logistics for films requiring strict temperature control increase delivery costs, yet the reputational surge of Aquestive Therapeutics (AQST) as a leader in drug delivery offsets these expenses. The company's P/E trend confirms a balance between value and earnings, where the current parameter equals -6.20. This underscores the potential of PharmFilm, a unique technology for creating soluble strips for CNS and allergy therapies.

AQST Aquestive Corp: Price to Earnings Ratio in the range 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for Aquestive Therapeutics Inc (AQST)

- price and consensus price forecast:
Stock Price Aquestive Pharma|AQST - Consensus Target
- market capitalization information:
Market Value Aquestive Pharma|AQST - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Aquestive Therapeutics|AQST - Company Net Assets|Market Cap to Book Value Multiple aquestive.com|AQST - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Aquestive Therapeutics|AQST - Long-Term Debt to Capital|Current Liabilities to Capital aquestive.com|AQST - Company Debts|Debt to Net Assets Ratio Aquestive Therapeutics Inc|AQST - Company Long-Term Debts|Company Short-Term Debts Aquestive Therapeutics|Critical Liquidity aquestive.com
- business earnings and investment ratios data:
AQST - Net Income|Projected Future Earnings Aquestive Therapeutics|AQST - P/E Multiple|Projected Price to Earnings Ratio Aquestive Corp|AQST - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Aquestive Corp|AQST - Operating profit before deduction of amortization|Earnings per share for the last four quarters Aquestive Therapeutics|AQST - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months aquestive.com|AQST - Net earnings per share growth this year|Net earnings per share growth forecast for next year Aquestive Therapeutics
- issuer revenue and sales details:
AQST - Revenue and Sales Volume|Company Expected Sales Volume Aquestive Pharma|AQST - Market Cap to Revenue|Forward Price to Sales Aquestive Corp|AQST - Revenue Growth YoY (Last 12 Months)
Comprehensive company analysis:Aquestive Therapeutics, Inc. - AQST
Flagship merchandise of Aquestive Therapeutics, Inc.

The P/E ratio reflects the market value of a single unit of profit, demonstrating investors' willingness to pay a premium for future capitalization growth relative to current accounting metrics. In the case of Aquestive Therapeutics (AQST), this metric assesses expectations regarding the commercialization of adrenaline films and patent protection, making the company's P/E valuation an indicator of market confidence in FDA approval and the success of the new drug delivery system.

Key competitors

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)